Axa
MLTX icon

Axa’s MoonLake Immunotherapeutics MLTX Stock Holding History

Axa’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-83,839
Closed -$3.96M – 670
2025
Q2 		$3.96M Sell
83,839
-20,205
-19% -$823K 0.01% 610
2025
Q1 		$4.06M Sell
104,044
-134
-0.1% -$5.77K 0.01% 593
2024
Q4 		$5.64M Sell
104,178
-164
-0.2% -$8.37K 0.02% 511
2024
Q3 		$5.26M Buy
104,342
+28
+0% +$1.31K 0.02% 532
2024
Q2 		$4.59M Buy
104,314
+59
+0.1% +$2.5K 0.01% 548
2024
Q1 		$5.24M Buy
104,255
+29
+0% +$1.57K 0.02% 546
2023
Q4 		$6.29M Sell
104,226
-19,165
-16% -$988K 0.02% 496
2023
Q3 		$7.03M Sell
123,391
-31,541
-20% -$1.74M 0.02% 467
2023
Q2 		$7.9M Sell
154,932
-146,422
-49% -$3.94M 0.03% 454
2023
Q1 		$6.45M Sell
301,354
-103,930
-26% -$1.75M 0.02% 504
2022
Q4 		$4.26M Buy
+405,284
New +$3.6M 0.02% 645

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Axa's MLTX Position: Q3 2025 in Review

Axa sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 83,839 shares — an estimated $3.96M sold.

Axa first reported a position in MLTX in Q4 2022 and held it in 11 quarters. The position peaked at $7.9M in Q2 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Axa reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 83,839 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $3.96M.
  • Axa first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 11 quarters.
  • Axa's MoonLake Immunotherapeutics position peaked at $7.9M in Q2 2023.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.